2-(4-(Chloromethyl)-1H-pyrazol-1-yl)pyridine, 95.0%, 1g

Methyl 8-(tert-butyl)-6-chloroimidazo[1,2-b]pyridazine-2-carboxylate, 97.0%, 100mg

Methyl 5-bromothiazole-4-carboxylate, 97.0%, 5g

(3-Bromophenyl)acetaldehyde, 95.0%, 1g

iScope IS.1153-PLPHi Triocular with Plan phase IOS objectives and Rackless cross table (infinity)

1-(3-Aminophenyl)-2,2,2-trifluoroethan-1-one, 97%, 250mg

1-BOC-3-(CBZ-AMINO)AZETIDINE-3-METHANOL, 95.0%, 250mg

2-(2-Bromoethyl)-1,3-Dioxolane, 97.00%, 1g

1-BOC-5-fluoroindole-2-boronic acid, 95.0%, 250mg

2,2-Dimethyl-1,3-dioxan-5-one, 95.0%, 1g

(2R,6R)-tert-Butyl 2,6-dimethylpiperazine-1-carboxylate, 95.0%, 10g

N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-proline>98.0%(HPLC)(T)5g

3-Vinylpyridine (stabilised with TBC), 97.0%, 1g